Foghorn Total Revenue from 2010 to 2025

FHTX Stock  USD 4.34  0.36  9.05%   
Foghorn Therapeutics Total Revenue yearly trend continues to be fairly stable with very little volatility. Total Revenue is likely to outpace its year average in 2025. Total Revenue is the total amount of income generated by the sale of goods or services related to Foghorn Therapeutics' primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2019-09-30
Previous Quarter
6.9 M
Current Value
7.8 M
Quarterly Volatility
4.3 M
 
Covid
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Foghorn Therapeutics over the last few years. Total revenue comprises all receipts Foghorn Therapeutics generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Foghorn Therapeutics' Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Foghorn Total Revenue Regression Statistics

Arithmetic Mean8,478,276
Geometric Mean0.00
Coefficient Of Variation183.53
Mean Deviation12,498,789
Median0.00
Standard Deviation15,560,212
Sample Variance242.1T
Range41.2M
R-Value0.76
Mean Square Error109.5T
R-Squared0.58
Significance0.0006
Slope2,484,397
Total Sum of Squares3631.8T

Foghorn Total Revenue History

202541.2 M
202439.3 M
202334.2 M
202219.2 M
20211.3 M
2020430 K

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Total Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue39.3 M41.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.